Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders
Company expects strong organic growth in sales, EBITDA in 2022
Technology adoption helped the industry to sail through Covid-19 disruption as it understood the need to digitize, learn, and excel
Revenue of $1.67 billion represents 8% reported growth; and up 9% on a core(basis.
AptarGroup acquired Voluntis and 80% of Weihai Hengyu Medical Products in 2021.
Key takeaways of Q3FY22 quarter & conference call highlights
Key takeaways of recent quarter & conference call highlights
Key takeaways of recent quarter & conference call highlights
Sun Pharma’s Q3FY22 operational performance was in line with I-direct estimates with sustained momentum and good growth across businesses
ICICI Direct analysis of Dr Reddy’s Q3FY22 results
Subscribe To Our Newsletter & Stay Updated
